Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y237

UPID:
PIN4_HUMAN

ALTERNATIVE NAMES:
Parvulin-14; Parvulin-17; Peptidyl-prolyl cis-trans isomerase Pin4; Peptidyl-prolyl cis/trans isomerase EPVH; Rotamase Pin4

ALTERNATIVE UPACC:
Q9Y237; A8E0G6; B3KXM0; F5H1P5; Q0D2H3; Q3MHV0; Q52M21; Q5HYW6; Q6IRW4

BACKGROUND:
The protein Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4, with aliases such as Peptidyl-prolyl cis/trans isomerase EPVH and Rotamase Pin4, is integral to the formation of ribosomes, binding to specific DNA regions. It exists in multiple isoforms, each with distinct DNA binding capabilities, highlighting its versatile role in cellular machinery.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 unveils potential avenues for therapeutic intervention. Its critical involvement in ribosomal RNA processing and DNA binding positions it as a key target for the development of novel drug therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.